MedTrace Logo

Effect of Silibinin(A) as a Potential Anti-obesity Agent

NCT05069298 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-06-23

No results posted yet for this study

Summary

Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat.

Therefore, the investigators want to carry out the present trial in order to confirm that Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat absorption and therefore will decrease the amount of energy from food intake.

Considering that milk thistle has been extensively studied in humans as liver-protector, the investigators consider that the use of human subjects will be of great interest to accelerate the employment of this compound to improve the effectiveness of dietary treatment in overweight/obese subjects.

Conditions

Interventions

DIETARY_SUPPLEMENT

Silibinin A

The compound will be administered following a 300 mg / 3 day schedule, before each main meal.

Sponsors & Collaborators

  • Universidad Católica San Antonio de Murcia

    lead OTHER

Principal Investigators

  • Juan José Hernández Morante, PhD · Catholic University of Murcia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-12
Primary Completion
2023-12-01
Completion
2023-12-21

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05069298 on ClinicalTrials.gov